BACK TO CONGRESSES

ASCO GI 2026

Jan 8 - 10, 2026 | San Francisco, CA

The agents listed below are currently under investigation. Their safety and efficacy have not been established.

Poster
Phase 1/2 Study of ARV-806, a PROTAC KRAS G12D Degrader, in KRAS G12D-mutated Advanced Solid Tumors, including Pancreatic Cancer

YR Murciano-Goroff et al.

VIEW MATERIAL